VRPX Insider Trading (Virpax Pharmaceuticals)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $716.00
Insider Selling (Last 12 Months): $0.00
Virpax Pharmaceuticals Insider Trading History Chart
Virpax Pharmaceuticals Share Price & Price History
$3.84
As of 06/22/2021 01:25 PM ET
Is this Seattle Penny Pot Stock a Potential Blockbuster?
From All Marijuana Stocks | Ad
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021
Virpax Pharmaceuticals Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/17/2021 | Thani Jambulingam | Director | Buy | 100 | $7.16 | $716.00 | 100 |  |
SEC Filings (Institutional Ownership Changes) for Virpax Pharmaceuticals (NASDAQ:VRPX)
5.55% of Virpax Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Virpax Pharmaceuticals Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 5/14/2021 | HN Saltoro Capital LP | 27,000 | $0.13M | 0.0% | N/A | 0.546% |  |
Data available starting January 2016
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Read More on Virpax Pharmaceuticals
Volume
1,708 shs
Average Volume
252,829 shs
Market Capitalization
$19.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Virpax Pharmaceuticals?
Virpax Pharmaceuticals' top insider investors include:
- Thani Jambulingam (Director)
Who are the major institutional investors of Virpax Pharmaceuticals?
Virpax Pharmaceuticals' top institutional shareholders include:
- HN Saltoro Capital LP — 0.55%
Which institutional investors are buying Virpax Pharmaceuticals stock?
Within the previous quarter, VRPX stock was acquired by institutional investors including:
- HN Saltoro Capital LP
